Benitec Biopharma (NASDAQ:BNTC) Price Target Raised to $22.00 at Citizens Jmp

Benitec Biopharma (NASDAQ:BNTC) had its target price boosted by research analysts at Citizens Jmp from $20.00 to $22.00 in a note issued to investors on Tuesday,Benzinga reports. The brokerage currently has a “market outperform” rating on the biotechnology company’s stock. Citizens Jmp’s target price would suggest a potential upside of 38.71% from the stock’s current price.

Several other equities research analysts also recently commented on BNTC. TD Cowen started coverage on Benitec Biopharma in a report on Monday, July 7th. They issued a “buy” rating for the company. Wall Street Zen upgraded shares of Benitec Biopharma from a “sell” rating to a “hold” rating in a research note on Saturday, October 25th. Weiss Ratings reissued a “sell (d-)” rating on shares of Benitec Biopharma in a report on Wednesday, October 8th. JMP Securities reissued a “market outperform” rating and set a $20.00 price target on shares of Benitec Biopharma in a report on Wednesday, September 24th. Finally, Citigroup reiterated an “outperform” rating on shares of Benitec Biopharma in a research report on Tuesday. One investment analyst has rated the stock with a Strong Buy rating, eight have given a Buy rating and two have given a Sell rating to the company. Based on data from MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and a consensus price target of $24.33.

Benitec Biopharma Stock Down 3.1%

NASDAQ:BNTC opened at $15.86 on Tuesday. Benitec Biopharma has a 1-year low of $9.10 and a 1-year high of $17.15. The company has a debt-to-equity ratio of 0.01, a current ratio of 54.67 and a quick ratio of 54.67. The firm’s 50-day moving average price is $14.42 and its 200-day moving average price is $13.76. The company has a market capitalization of $416.33 million, a PE ratio of -10.79 and a beta of 0.41.

Benitec Biopharma (NASDAQ:BNTC) last released its earnings results on Thursday, September 25th. The biotechnology company reported ($0.42) EPS for the quarter, missing the consensus estimate of ($0.24) by ($0.18). On average, equities analysts predict that Benitec Biopharma will post -1.48 EPS for the current fiscal year.

Hedge Funds Weigh In On Benitec Biopharma

A number of institutional investors have recently bought and sold shares of the stock. Police & Firemen s Retirement System of New Jersey bought a new position in shares of Benitec Biopharma in the second quarter worth about $38,000. JPMorgan Chase & Co. purchased a new stake in Benitec Biopharma during the 2nd quarter valued at approximately $80,000. Bank of America Corp DE grew its position in shares of Benitec Biopharma by 2,255.8% during the second quarter. Bank of America Corp DE now owns 6,879 shares of the biotechnology company’s stock valued at $80,000 after purchasing an additional 6,587 shares in the last quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. purchased a new stake in shares of Benitec Biopharma in the second quarter worth about $93,000. Finally, New York State Common Retirement Fund purchased a new position in Benitec Biopharma during the 2nd quarter valued at approximately $95,000. 52.19% of the stock is owned by institutional investors.

About Benitec Biopharma

Benitec Biopharma Inc, a clinical-stage biotechnology company, focuses on the development of novel genetic medicines. The company develops DNA-directed RNA interference-based therapeutics for chronic and life-threatening human conditions. It is developing BB-301, an adeno-associated virus based gene therapy agent for treating oculopharyngeal muscular dystrophy.